(INCY) Incyte - Ratings and Ratios

Incyte Corporation, a biopharmaceutical company, specializes in the discovery, development, and commercialization of innovative therapeutics, primarily in the United States, Europe, Canada, and Japan. Their product portfolio includes JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor for myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. MONJUVI (tafasitamab-cxix) is a CD19-targeting antibody for relapsed/refractory diffuse large B-cell lymphoma. PEMAZYRE (pemigatinib) is a FGFR kinase inhibitor for biliary tract cancer and cholangiocarcinoma. ICLUSIG (ponatinib) targets the BCR-ABL mutation in CML and Ph+ ALL. ZYNYZ (retifanlimab-dlwr) treats Merkel cell carcinoma, while NIKTIMVO (axatilimab-csfr) addresses chronic graft-versus-host disease. OPZELURA (ruxolitinib) cream is the first topical JAK inhibitor for atopic dermatitis.

Their clinical pipeline includes INCB123667 (CDK2 inhibitor) for ovarian cancer, INCB161734 (KRASG12D inhibitor) for solid tumors, and INCA33890 (bispecific TGF-β/PD-1 inhibitor) for immune modulation. Ruxolitinib cream is under study for hidradenitis suppurativa, while Povorcitinib targets multiple inflammatory conditions. INCB000262 and INCB000547 focus on MRGPRX2/4 for itching and neuro-immune disorders. INCA034460 (anti-CD122) aims at vitiligo, and Zilurgisertib (ALK2 inhibitor) targets fibrodysplasia ossificans progressiva.

Incyte collaborates with Genesis Therapeutics, leveraging AI for drug discovery. Products are distributed through pharmacies and wholesalers. Originally named Incyte Genomics, the company rebranded in 2003 and is headquartered in Wilmington, Delaware, a hub for biotech and corporate law.

Based on the data, INCYs stock is below its 20, 50, and 200-day SMAs, indicating bearish momentum. The ATR of 2.55 suggests moderate volatility. Fundamentally, the high P/E of 388 contrasts with a forward P/E of 9.62, signaling growth expectations. The P/B ratio of 3.27 reflects growth prospects, while the RoE of 0.95 indicates lower profitability. The 3-month forecast suggests cautious optimism, with potential downside risk due to technical weakness but positive pipeline developments.